Protease-deleted adenovirus as an alternative for replication-competent adenovirus vector

Par Conseil national de recherches du Canada

Téléchargement	Voir la version finale : Protease-deleted adenovirus as an alternative for replication-competent adenovirus vector (PDF, 3.4 Mio) Voir les données supplémentaires : Protease-deleted adenovirus as an alternative for replication-competent adenovirus vector (PDF, 852 Kio)
DOI	Trouver le DOI : https://doi.org/10.1016/j.virol.2023.07.009
Auteur	Rechercher : Elahi, S. Mehdy¹Identifiant ORCID : https://orcid.org/0000-0003-2040-5665; Rechercher : Nazemi-Moghaddam, Nazila¹; Rechercher : Gilbert, Rénald¹Identifiant ORCID : https://orcid.org/0000-0002-8265-2111
Affiliation	Conseil national de recherches Canada. Thérapeutique en santé humaine
Bailleur de fonds	Rechercher : National Research Council Canada
Format	Texte, Article
Sujet	protease-deleted adenovirus; single-cycle adenovirus vector; replication-competent adenovirus vector; replication-defective adenovirus; adenovirus E4 region
Résumé	For cancer therapy and vaccination an amplified expression of the therapeutic gene is desired. Previously, we have developed a single-cycle adenovirus vector (SC-AdV) by deleting the adenovirus protease (PS) gene. In order to keep the E1 region intact within the PS-deleted adenoviruses, we examined the insertion of two transgenes under the control of a constitutive or inducible promoters. These were inserted between E4 and the right inverted terminal repeat in a wide variety of backbones with various combinations of PS, E3 and E4 deletion. Our data showed that PS-deleted adenoviruses, expressed transgenes as strongly as replication-competent AdVs in HEK293A and a variant of HeLa cells. In a head-to-head comparison in four human cell lines, we demonstrated that SC-AdV, was comparable for transgene expression efficacy with its replication-competent counterpart. However, the SC-AdV expresses its transgene 10 to 16,000 times higher than its replication-defective counterpart.
Date de publication	2023-07-19
Maison d’édition	Elsevier
Licence	Licences d'utilisation proposées par Elsevier https://www.elsevier.com/about/policies-and-standards/open-access-licenses/user
Dans	Virology 586, nº C (septembre 2023) : 67–75.
Langue	anglais
Publications évaluées par des pairs	Oui
Identificateur	S0042682223001484
Exporter la notice	Exporter en format RIS
Signaler une correction	Signaler une correction (s'ouvre dans un nouvel onglet)
Identificateur de l’enregistrement	32ca8bb2-9ad9-421a-8689-8516f1fbef7c
Enregistrement créé	2024-10-28
Enregistrement modifié	2025-11-03

Date de modification :: 2026-02-12